Interestingly, the use of CDK4/6-specific inhibitor palbociclib was reported to efficiently inhibit tumor cell growth in vitro in chordoma cell line models32, providing the rationale for clinical trials evaluating the efficacy of palbociclib in chordoma. This evidence concerns the gene CDK4 and chordoma.